catalog number :
MBS311950
products full name :
MAb to EGF Receptor (ligand binding site)
products short name :
Epidermal Growth Factor Receptor (EGFR) (extracellular ligand binding site
products name syn :
Monoclonal Antibody to Human Epidermal Growth Factor (EGF) Receptor (Extracellular ligand binding site)
other names :
epidermal growth factor receptor; Epidermal growth factor receptor; epidermal growth factor receptor; OTTHUMP00000159661; OTTHUMP00000159662; OTTHUMP00000159663; OTTHUMP00000209210; OTTHUMP00000209211; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
other gene names :
EGFR; EGFR; ERBB; HER1; mENA; ERBB1; PIG61; ERBB1
uniprot entry name :
EGFR_HUMAN
host :
Host: Mouse. Source: Tissue Culture Supernatant
specificity :
Epidermal Growth Factor Receptor (EGFR) (extracellular ligand binding site. Human EGF Receptor (extracellular ligand binding site). Does not cross react with v-erb-B.
purity :
Protein G chromatography
form :
Purified, Lyophilized. Reconstitute with 10ul double distilled water.
concentration :
1mg/ml (prior to lyophilization)
storage stability :
Store lyophilized product at 2 to 8 degree C. After reconstitution, store at -20 degree C. Avoid multiple freeze/thaw cycles.
tested application :
Block, EIA/ELISA, Flow Cytometry, Immunohistochemistry - Paraffin
other info1 :
Immunogen: Human EGF Receptor. Affinity Constant: Not determined.
other info2 :
Buffer: PBS, pH 7.4. Preservative: 0.1% Sodium Azide. Lyophilized: Yes. Important Note: Vial Contains Small Quantity. Centrifuge Product Before Opening. Warnings: This product contains sodium azide, which has been classified as Xn (Harmful), in European Directive 67/548/EEC in the concentration range of 0.1 - 1.0 %. When disposing of this reagent through lead or copper plumbing, flush with copious volumes of water to prevent azide build-up in drains.
products categories :
Monoclonal Antibodies to Cytokines and Growth Factors
products references :
Manneck, H.E., et al., (1993), "Enzyme-linked Immunosorbent Assay for the Determination of Epidermal Growth Factor Receptor", Klin. Lab., 39:177-182. Roth, H.J., et al., (1994), "Is it necessary for a Quantitative EGF Receptor A
ncbi acc num :
AAA63171.1
ncbi mol weight :
134,277 Da
ncbi pathways :
Adherens Junction Pathway (83070); Adherens Junction Pathway (481); Alpha6-Beta4 Integrin Signaling Pathway (198807); Androgen Receptor Signaling Pathway (198806); Arf6 Signaling Events Pathway (138034); Axon Guidance Pathway (105688); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Calcium Signaling Pathway (83050); Calcium Signaling Pathway (459)
ncbi summary :
The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. Multiple alternatively spliced transcript variants that encode different protein isoforms have been found for this gene. [provided by RefSeq]
uniprot summary :
Function: Cell surface receptor for EGF, but also for other members of the EGF family, such as TGF-alpha, BTC/betacellulin, AREGAREGB/amphiregulin, HBEGF, GP30 and vaccinia virus growth factor. Ligand binding triggers a conformation change, leading to activation of the kinase and subsequent phosphorylation of down-stream protein kinases. Is involved in the control of cell growth, proliferation and differentiation. Phosphorylates MUC1 in breast cancer cells and increases the interaction of MUC1 with SRC and CTNNB1/beta-catenin. Ref.33 Ref.54 Ref.55 Ref.56 Ref.60 Ref.63 Ref.65Isoform 2 may act as an antagonist of EGF action. Ref.33 Ref.54 Ref.55 Ref.56 Ref.60 Ref.63 Ref.65. Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. Ref.56 Ref.59 Ref.60 Ref.61 Ref.62 Ref.63. Subunit structure: EGF binding triggers dimerization of the receptor and promotes autophosphorylation. The activate receptor dimer binds one EGF molecule. Heterodimer with ERBB2. Interacts with ERRFI1. Interaction with ERRFI1 inhibits dimerization of the kinase domain and autophosphorylation. Binds RIPK1. Interacts (via autophosphorylated C-terminal tail) with CBL. Part of a complex with ERBB2 and either PIK3C2A or PIK3C2B. Interacts (autophosphorylated form) with PIK3C2B; the interaction may be indirect. Interacts with PELP1. Binds MUC1. Interacts with AP2M1. Interacts with GAB2. Interacts with COPG, upon EGF treatment; interaction is essential for regulation of EGF-dependent nuclear transport of EGFR by retrograde trafficking from the Golgi to the ER. Interacts with TNK2; this interaction is dependent on EGF stimulation and kinase activity of EGFR. Ref.26 Ref.28 Ref.31 Ref.32 Ref.33 Ref.37 Ref.41 Ref.44 Ref.52 Ref.54 Ref.55 Ref.60 Ref.62 Ref.63 Ref.64 Ref.65. Subcellular location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus membrane; Single-pass type I membrane protein. Nucleus membrane; Single-pass type I membrane protein. Endosome. Note: In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER. Co-localizes with TNK2 on the endosomes. Ref.41 Ref.52 Ref.54 Ref.63Isoform 2: Secreted Ref.41 Ref.52 Ref.54 Ref.63. Tissue specificity: Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers. Ref.40. Post-translational modification: Phosphorylation of Ser-695 is partial and occurs only if Thr-693 is phosphorylated. Ref.17 Ref.25 Ref.30 Ref.34 Ref.35 Ref.36 Ref.38 Ref.39 Ref.42 Ref.43 Ref.45 Ref.46 Ref.47 Ref.48 Ref.50 Ref.51 Ref.59 Ref.60 Ref.62 Ref.63Monoubiquitinated and polyubiquitinated upon EGF stimulation; which does not affect tyrosine kinase activity or signaling capacity but may play a role in lysosomal targeting. Polyubiquitin linkage is mainly through 'Lys-63', but linkage through 'Lys-48', 'Lys-11' and 'Lys-29' also occur. Involvement in disease: Defects in EGFR are associated with lung cancer (LNCR) [. MIM:211980]. Miscellaneous: Binding of EGF to the receptor leads to dimerization, internalization of the EGF-receptor complex, induction of the tyrosine kinase activity, stimulation of cell DNA synthesis, and cell proliferation. Sequence similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.Contains 1 protein kinase domain.